ABBV-RGX-314 gene therapy yields 5-year safety, vision maintenance

A one-time injection of ABBV-RGX-314, a gene therapy for wet age-related macular degeneration, yielded reductions in treatment burden and strong visual acuity maintenance at 5 years with no new safety signals, according to a speaker.At the American Society of Retina Specialists annual meeting, Robert L. Avery, MD, of California Retina Consultants, presented long-term follow-up data on the